Your session is about to expire
← Back to Search
RP-3500 for Solid Cancers
Study Summary
This trial is testing a new drug, RP-3500, to see what dose is safe and effective for treating patients with solid tumors. The study will also look at the side effects of the drug and how it works in the body.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have recovered from all side effects of my previous cancer treatments or surgeries.I do not have any active, uncontrolled infections including HBV, HCV, HIV, or AIDS.I have been treated with ATR or DNA-PK inhibitors before.My cancer does not respond to standard treatments or I cannot tolerate them.My liver function is moderately or severely impaired.My cancer's biomarker profile is available from a certified lab test.I do not have any severe illnesses or conditions that could put me at risk.I can swallow and keep down pills.My organs are functioning well.I have a history of irregular heartbeats or risk factors like heart disease.I will use birth control during and for 6 months after the study, and won't donate sperm in this time.I don't have any health issues that could affect the study's results or my participation.I am fully active or can carry out light work.I haven't had cancer treatment in the last 14 days.I am allergic to ingredients in RP-3500 (camonsertib).I have signed and dated the consent form to participate in this study.I am taking medication that can affect my heart's rhythm.I have been diagnosed with MDS or AML.I am 18 years old or older.My high blood pressure is not under control.I do not have uncontrolled, symptomatic brain metastases.
- Group 1: RP-3500 (camonsertib) alone
- Group 2: Expansion cohorts with RP-3500 (camonsertib)
- Group 3: RP-3500 (camonsertib) with Talazoparib or Gemcitabine
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
To what medical maladies is RP-3500 a common remedy?
"RP-3500 has been approved for the management of urinary bladder, small cell lung cancer (SCLC), and head and neck carcinomas."
Have any further investigations been conducted regarding RP-3500?
"Presently, there are 501 extant clinical trials studying RP-3500 with 137 of these studies in the third phase. Despite most of the investigations being located in Adelaide, South Australia; a total of 26822 medical centres across the globe have research programs dedicated to this drug."
What is the full scope of locations where this experiment has been implemented?
"Nine medical centres are enrolling patients, among them being Participating Site 1006 in Boston, Participating Site 1002 in Toronto, and Participating Site 2001 in Providence. The other six locations can be found on the study's page."
What goals are being sought after through the execution of this scientific experiment?
"The principal endpoint for this research is the safety and tolerability of RP-3500, which will be observed up to three months after treatment. Secondary outcomes include characterizing the medication's pharmacokinetic profile via AUC 0-inf; assessing target engagement by measuring immunohistochemistry biomarkers such as gH2AX in pre and post biopsies; ascertaining preliminary anti-tumor activity with an overall response rate in eligible advanced solid tumors according to CT/MRI RECIST 1.1 or CA-125/PSA GCIG PSWG criteria."
Are applications for participation in this clinical investigation still being accepted?
"Affirmative, clinicaltrials.gov provides evidence that this medical trial is still recruiting participants as of the time of writing. The study was first introduced on July 22nd 2020 and most recently modified on September 9th 2022."
How many subjects are being monitored for this experiment?
"To meet the requirements of this clinical trial, 451 suitable candidates need to be enrolled. Those wishing to partake may do so from Participating Site 1006 in Boston or Participating Site 1002 in Toronto."
Share this study with friends
Copy Link
Messenger